






PREDICTORS FOR DIRECT AND INDIRECT COSTS IN
PARKINSON’S DISEASE
Siebert U1, Bornschein B2, Spottke EA3, Berger K4, Oertel WH5,
Dodel R3
1Harvard Medical School, Boston, MA, USA; 2University of Munich,
Munich, Germany; 3University of Bonn, Bonn, Germany; 4MERG
Medical Economics Research Group, Munich, Germany; 5University of
Marburg, Marburg, Germany
OBJECTIVES: Parkinson’s disease (PD) is a frequent and chronic
neurological disorder representing a growing burden for national
health care budgets. We assessed independent predictors for 1)
PD-speciﬁc drug costs; 2) direct non-drug costs’; and 3) indirect
costs METHODS: We analyzed data from an ongoing prospec-
tive cost study (n = 157) within the German PD Competence
Network using multivariate regression techniques. Potential pre-
dictors included sociodemographic factors, clinical data repre-
sented by the Uniﬁed Parkinson’s Disease Rating Scale (UPDRS),
disease severity (Hoehn&Yahr scale) and quality of life (QoL)
data. PD-speciﬁc drug costs and non-drug costs were log-trans-
formed prior to model development, resulting in multiplicative
models. Indirect costs were calculated using the human capital
approach. Model formulation proceeded in two steps: ﬁrst, pres-
ence of indirect costs was modeled by logistic regression, and
second, costs were predicted by linear regression in the subgroup
of patients with indirect costs. RESULTS: Predictors of PD-spe-
ciﬁc drugs included age, sex, clinical state (all p < 0.001) and
QoL (p = 0.02). Non-drug direct costs were predicted by disease
stage p = 0.05 and p < 0.001) and QoL (p = 0.03). Presence of
indirect costs depended on age (p < 0.001), UPDRS (p = 0.03),
QoL (p = 0.04), presence of depression (p = 0.02), and falls (p
= 0.006). The magnitude of indirect costs was predicted by
UPDRS (p = 0.003) and falls (p = 0.007). Variance explained by
the predictors (adjusted R-squared) ranged from 24% to 28%
for all models. CONCLUSIONS: Based on our analysis, clinical
and QoL variables are the most relevant predictors of PD cost.
However, we cannot infer from this study whether improved
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OBJECTIVES: Studies from Europe and the USA demonstrate
that entacapone + levodopa signiﬁcantly improves the function-
ality of Parkinson’s disease (PD) patients with wearing-off, and
is cost-effective compared to standard of care (SOC). This study
aimed to evaluate the cost-effectiveness of new levodopa/car-
bidopa/entacapone (Stalevo) vs. SOC in wearing-off patients in
the UK. METHODS: Cost-utility analysis was performed using
a Markov model based on Modiﬁed Hoehn and Yahr (H&Y)
stages. Transition probabilities were obtained from two multi-
national, double-blind RCTs. Mean costs and EQ-5D utilities of
local PD population were used with 3.5% discounting. NHS
drug costs were obtained from MIMS. Levodopa doses and
initial patient distribution by H&Y were derived from data of
wearing-off patients from a Finnish cost-of-illness study. Adap-
tations to local setting were based on expert opinions. Mean lev-
odopa/carbidopa/entacapone intake was 4.8 tablets/day. Both A)
societal and B) the NHS perspective was considered. Costs to
society included NHS costs, social costs and PD-related private
expenditures. RESULTS: A) New levodopa/carbidopa/enta-
capone treatment provided signiﬁcantly better quality of life
(QoL) for the patients (+0.817 QALYs). Simultaneously the costs
to society decreased by 8200GBP, mainly due to savings in social
costs and secondary care. The 10-year total direct costs to society
were 58,400GBP/patient on levodopa/carbidopa/entacapone. B)
Per patient the 10-year costs to NHS increased by 5500GBP,
resulting in total NHS costs of 26,300GBP. Thus, from the NHS
perspective, levodopa/carbidopa/entacapone was associated with
an incremental cost of 6700GBP/QALY gained. Both results
were robust to sensitivity analyses. CONCLUSIONS: New lev-
odopa/carbidopa/entacapone treatment provides better QoL for
wearing-off patients, simultaneously reducing the costs to UK
society, compared to SOC. Although the NHS costs slightly
increase, the incremental cost/QALY gained is relatively low.
Therefore, from a societal, as well as NHS perspective, use of
new levodopa/carbidopa/entacapone treatment in PD patients
with wearing-off is economically justiﬁed.
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OBJECTIVES: Retrospectively assess the total costs of Parkin-
son Disease (PD) in Italy from a societal perspective.
METHODS: We dispensed a questionnaire to PD patients
divided in three sections: Economic (14 items) Quality of life (36
items) Care Giver Burdens (8 items. We included 268 patients
with idiopathic PD, according to the CAPIT criteria. Those
patients are representative of the population of 7500 movement
disorder patients referring to our medical centre. The study pop-
ulation were divided in 3 groups accordingly to the classiﬁcation
of the Hoehn and Yahr staging scale. Costs of each group were
assessed. The distribution of patients is spread on all the Italian
territory. RESULTS: The mean annual direct cost of PD is
5639.12€. Drug therapy counts for 32.8% of total cost (1849€),
rehabilitation for 19.44% (1.096€), inpatient hospital care for
19.61% (1105.83€), “out of pocket” patient expenses (private
visits, paid rehabilitation, home care) count for 18.53%
(1044.93€), Specialist and Gp visit for 5.92% (333.84€). As the
severity of the disease grows the PD costs turns form National
Health System to patient “out of pocket” expenses. Costs are
signiﬁcantly higher when patient suffers from motor ﬂuctuations.
QoL reduces dramatically as the PD symptoms worsen. CON-
CLUSIONS: This study shows that PD represents a relevant
monetary burden for the society associated to a signiﬁcant
worsen of QoL. The total cost of this disease, based on an esti-
mation of 160.000 idiopathic PD patients in Italy, is about
€76,000,000 per year. Moreover, due to the demographic ten-
dency in our country we can assume an increase of this value in
the coming years.
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OBJECTIVES: To estimate the resources use and associated
direct costs of hospital care for primary stroke patients in
Poland. METHODS: Study design: The prospective, bottom-up,
naturalistic, multicenter cost of illness study. Patients: Primary
stroke patients successively admitted to three hospital centers of
different institution. Data on clinical characteristics (i.e. risk
factors, prestroke status, clinical state on admission and 
discharge) and hospital resources use (i.e. type of ward state,
diagnostic and therapeutic procedures, drugs, specialists’ con-
sultations and other medical professionals work, transport) were
collected. Unit costs for all resources used were calculated using
participating hospitals account systems and other available tariff
tables. Extensive sensitivity analysis was performed using data
on large number of stroke patients hospitalized in over 40 centers
in 2001 and 2002. Values are expressed in zl (1USD = 1.95zl;
1Euro = 2.32 purchasing power parities). RESULTS: One
hundred sixty-four patients were enrolled (mean age:71.4;
man:40.6%). Strokes were diagnosed as ischaemic in 85.8%,
hemorrhagic in 8.02% and unclassiﬁed in 6.17%. Mean hospi-
tal stay was 12.3 days, including 1.4 days on high dependency
ward, 6.9 days on stroke unit and 3.8 days on general ward.
Total cost of hospital service amounted for 5258zl (95%CI:
4880;5663), with one-ﬁfth due to variable costs, i.e. diagnostic
and therapeutic procedures (451zl), drugs (262zl), consultations
(35zl), work costs (241zl) and transport (123zl). CONCLU-
SIONS: The resources use and associated direct cost of hospital
care for primary stroke patients in Poland are substantial,
although ﬁxed costs represent majority of it.
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OBJECTIVES: Stroke imposes a considerable economic burden
on the individual and society. Recently, the concept of an inte-
grated stroke unit has been established in several countries to
improve the outcome of patients. This study evaluates the costs
of acute care of the different cerebrovascular insults on a stroke
unit. METHODS: All patients included were consecutively
admitted to the Department of Neurology, Philipps University
Marburg, with the diagnosis of stroke or transient ischemic
attacks (TIAs) between 1st January and 30th June 2000 (n =
340). Clinical status and course were evaluated by using the
Barthel index and the modiﬁed Rankin scale. Employing a
“bottom-up” approach, we calculated the costs from the per-
spective of the hospital and the third party payer using data from
provider departments and other published sources. RESULTS:
In-patient costs were €3020 (US-$3320), €3480 (US-$3840),
€5080 (US-$5590) for TIA, ischemic stroke (IS) and intracere-
bral hemorrhage (ICH), respectively. Patient sub-groups ranked
in the same order for average length of stay (LOS) at 9.4d for
TIA, 10.2d for IS and 11.9d for ICH. Approximately, 30% of
the hospital costs are due to physician charges and care. Imaging
was 10% and lab investigations were 14% of total costs, inde-
pendent of the diagnosis. Post-acute treatment, including in-
patient rehabilitation, amounted to €9880. In all patients
independent of the diagnosis a considerable clinical improvement
was found at time of discharge. CONCLUSIONS: Care of
patients with cerebrovascular events in a stroke unit causes a
high demand of resources and has a considerable impact on
healthcare expenditure. Therefore, more detailed comparative
investigations are necessary to evaluate the stroke unit concept
for a rationale use of available resources in patients with cere-
brovascular events.
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OBJECTIVES: To estimate the cost-effectiveness of intravenous
recombinant tissue plasminogen activator (rt-PA) therapy for
acute ischemic stroke from the perspective of Taiwan National
Health Insurance system. METHODS: A decision-analytic
model was developed to perform the cost-effectiveness analysis
of rt-PA treatment for acute ischemic stroke. We considered only
costs of hospitalization (initial acute care and recurrence)
because estimates of long-term care in Taiwan are not available.
The estimates of efﬁcacy of rt-PA were based on an updated
Cochrane systematic review of randomized trials of thromboly-
sis. Data on costs, health outcomes, and utilities of disability
were taken from a hospital-based study (360 ﬁrst-ever ischemic
stroke patients), national statistics, and literature-derived values.
Costs per quality-adjusted life-year (QALY) were calculated for
a hypothetical cohort of 1000 eligible patients, with starting age
65 years. RESULTS: The model suggested that over the lifetime
a patient treated with rt-PA (within 3 hours of stroke onset)
gained 0.21 QALYs, at a cost of NT$131,900 (US$4211) per
QALY. CONCLUSIONS: Using rt-PA in treating acute ischemic
stroke in Taiwan is likely to generate health beneﬁts at modest
extra costs.
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OBJECTIVES: From SISYPHE—a case-control study in occupa-
tional health institution in Paris area—we calculated indirect
costs associated to insomnia. METHODS: Number and duration
of work absence, reported retrospectively over the last 2-year
period by a group of insomniac employees and a group of good
sleeper employees, were basic data for the calculation of indirect
costs. We adopted the perspective of the Sickness Fund (SF) for
the private sector and the perspective of the employer (produc-
tivity) for the private and the public sector. The costing was per-
formed combining number and duration of work absence, the
level of incomes of employees in 2000, the annual number of
workdays, the SF rules and employer rules for the coverage of
workdays loss in private sector and the published added value
for the evaluation of loss of productivity. RESULTS: A total of
568 work absence were reported from 313 employees (public +
private sector). Average duration of work absence per employ-
ees were 12.9 days (±2.27) and 10.2 (±2.02) days for insomniac
and good sleeper respectively. Incremental cost associated to
insomnia in the perspective of the SF for employees of private
sector was estimated at 130€ per year for insomniac employee.
The rate of coverage by the SF represents 26% of the total cov-
erage (SF + employers). Incremental loss of productivity associ-
ated to insomnia is estimated at 1419€ per year for insomniac
employee. CONCLUSIONS: Design of SISYPHE allows us to
calculate indirect cost associated to insomnia. We observe SF
accounts only for one quarter of the total coverage. Loss of pro-
ductivity is 10-fold higher compared to SF coverage.
